Enhancement of vascular function by modulation of endogenous...

Details Enhancement of vascular function by modulation of endogenous... Enhancement of vascular function by modulation of endogenous...

2004-12-22

2008-11-18

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C424S094400, C424S439000, C424S441000, C426S648000, C426S656000

Reexamination Certificate

active

07452916

ABSTRACT:
Endothelial nitric oxide production is enhanced by administration of arginine or lysine as a dietary supplement. Enhanced nitric oxide production from arginine supplementation improves vascular function and structure. Additional compounds may be administered with arginine or lysine to further enhance nitric oxide activity, including calcium, vitamin B6, vitamin B12, vitamin C, vitamin B, coenzyme Q, carotene, or glutathione.

REFERENCES:
patent: 2878124 (1959-03-01), Krulkenberg
patent: 3015567 (1962-01-01), Hause et al.
patent: 3360374 (1967-12-01), Barr, Sr. et al.
patent: 3809759 (1974-05-01), Bocher et al.
patent: 3970750 (1976-07-01), Brockemeyer et al.
patent: 4168307 (1979-09-01), Okamoto et al.
patent: 4340592 (1982-07-01), Adibi
patent: 4900566 (1990-02-01), Howard
patent: 4920098 (1990-04-01), Cotter et al.
patent: 4957938 (1990-09-01), Anderson et al.
patent: 5008388 (1991-04-01), Ingberg et al.
patent: 5026721 (1991-06-01), Dudrick et al.
patent: 5028627 (1991-07-01), Kilbourn et al.
patent: 5032377 (1991-07-01), Rademachers et al.
patent: 5032608 (1991-07-01), Dudrick
patent: 5034377 (1991-07-01), Adibi et al.
patent: 5036052 (1991-07-01), Ozeki et al.
patent: 5041429 (1991-08-01), Sawai et al.
patent: 5106836 (1992-04-01), Clemens et al.
patent: 5157022 (1992-10-01), Barbul
patent: 5171217 (1992-12-01), March et al.
patent: 5217997 (1993-06-01), Levere et al.
patent: 5221668 (1993-06-01), Henningfield et al.
patent: 5229390 (1993-07-01), Moriyama et al.
patent: 5236413 (1993-08-01), Feiring
patent: 5248688 (1993-09-01), Dudrick
patent: 5262435 (1993-11-01), Joshua et al.
patent: 5278189 (1994-01-01), Rath et al.
patent: 5288490 (1994-02-01), Budzynski et al.
patent: 5296246 (1994-03-01), Inoue et al.
patent: 5326569 (1994-07-01), Acosta et al.
patent: 5334617 (1994-08-01), Ulrich et al.
patent: 5348755 (1994-09-01), Roy
patent: 5352695 (1994-10-01), N'Guyen et al.
patent: 5364644 (1994-11-01), Walaszek et al.
patent: 5372807 (1994-12-01), Poiani et al.
patent: 5374651 (1994-12-01), Kilbourn et al.
patent: 5380945 (1995-01-01), Murad et al.
patent: 5385940 (1995-01-01), Moskowitz
patent: 5428070 (1995-06-01), Cooke et al.
patent: 5464644 (1995-11-01), Wullschleger et al.
patent: 5482925 (1996-01-01), Hutsell
patent: 5499971 (1996-03-01), Shapland et al.
patent: 5543430 (1996-08-01), Kaesemeyer et al.
patent: 5576287 (1996-11-01), Zaloga et al.
patent: 5576351 (1996-11-01), Yoshimura et al.
patent: 5626883 (1997-05-01), Paul
patent: 5628730 (1997-05-01), Shapland et al.
patent: 5631031 (1997-05-01), Meade
patent: 5634895 (1997-06-01), Igo et al.
patent: 5650418 (1997-07-01), Rath et al.
patent: 5767160 (1998-06-01), Kaesemeyer
patent: 5780039 (1998-07-01), Greenberg et al.
patent: 5830848 (1998-11-01), Harrison et al.
patent: 5852058 (1998-12-01), Cooke et al.
patent: 5861168 (1999-01-01), Cooke et al.
patent: 5891459 (1999-04-01), Cooke et al.
patent: 5945452 (1999-08-01), Cooke et al.
patent: 5965529 (1999-10-01), Garfield et al.
patent: 6063432 (2000-05-01), Maxwell et al.
patent: 6083515 (2000-07-01), Garvey et al.
patent: 6117872 (2000-09-01), Maxwell et al.
patent: 6337321 (2002-01-01), Cooke et al.
patent: 6552074 (2003-04-01), Kimoto et al.
patent: 6642208 (2003-11-01), Cooke et al.
patent: 6646006 (2003-11-01), Cooke et al.
patent: 2002/0091160 (2002-02-01), Cooke et al.
patent: 0 259 167 (1988-03-01), None
patent: 0 441 119 (1991-08-01), None
patent: 0 483 614 (1992-05-01), None
patent: 0 546 796 (1992-06-01), None
patent: 0 511 118 (1992-10-01), None
patent: 511587 (1992-11-01), None
patent: 0511587 (1992-11-01), None
patent: 0 546 796 (1993-06-01), None
patent: 546796 (1993-06-01), None
patent: 259167 (1998-03-01), None
patent: FN 68970 (1985-12-01), None
patent: 2 507 892 (1982-12-01), None
patent: 2547501 (1984-12-01), None
patent: 953997 (1964-04-01), None
patent: 1304499 (1973-01-01), None
patent: 2 100 982 (1982-06-01), None
patent: 50-48189 (1975-04-01), None
patent: 57-5692 (1982-01-01), None
patent: 57-93913 (1982-06-01), None
patent: 58-55418 (1983-04-01), None
patent: 58-55418 (1983-04-01), None
patent: 59-210872 (1984-11-01), None
patent: 60-049764 (1985-03-01), None
patent: 60-094075 (1985-05-01), None
patent: 61-215323 (1986-09-01), None
patent: 61-254162 (1986-11-01), None
patent: 63-502558 (1988-09-01), None
patent: 3-21786 (1991-01-01), None
patent: 3-505036 (1991-11-01), None
patent: 5-163139 (1993-06-01), None
patent: 5-507226 (1993-10-01), None
patent: 6-321786 (1994-11-01), None
patent: 7-163269 (1995-06-01), None
patent: WO 85/00517 (1985-02-01), None
patent: WO 87/04602 (1987-08-01), None
patent: WO 88/01872 (1988-03-01), None
patent: WO 89/05345 (1989-06-01), None
patent: WO 91/07188 (1991-05-01), None
patent: WO 92/08472 (1992-05-01), None
patent: WO 93/00052 (1993-01-01), None
patent: WO 93/10097 (1993-05-01), None
patent: WO 93/18156 (1993-09-01), None
patent: WO 94/16729 (1994-08-01), None
patent: WO 94/28721 (1994-12-01), None
patent: WO 95/05866 (1995-03-01), None
patent: WO 95/24898 (1995-09-01), None
patent: WO 96/00112 (1996-01-01), None
patent: WO 97/16983 (1997-05-01), None
patent: WO 98/18491 (1998-05-01), None
patent: 93-6619 (1993-09-01), None
patent: 94/10015 (1995-11-01), None
patent: 9410015 (1995-11-01), None
Castillo et al. Proceedings of the National Academy of Science USA. vol. 90, No. 1, pp. 193-197.
McNamara et al. Biochemical and Biophysical Research Communications. May 28, 1993, vol. 193, No. 1, pp. 291-296.
Unither Pharma, Inc. et al. v.The Daily Wellness Company et al., Order Following Claim Construction Hearing, In the U.S. District Court for the Northern District of California, San Jose Division, Case No. C 02-05284 JW (Related Cases: No. C 03-5090 JW; No. C 03-5878 JW); filed Nov. 30, 2005, 36 pgs.
Unither Pharma, Inc. et al. v.Herbalife International, Inc., Herbalife's Final Invalidity Contentions and Exhibit A (Patent Local Rule 3-6), in the U.S. District Court, Northern District of California, San Jose Division, Case No. C03-5090 JW (Related Cases: C03-5878 JW, C03-0415 JW and C02-5284 JW), filed Jan. 19, 2006, 10 pgs.
Unither Pharma, Inc. et al. v.Herbalife International, Inc., Herbalife's Final Invalidity Contentions and Exhibits A-D (Patent Local Rule 3-6), in the U.S. District Court, Northern District of California, San Jose Division, Case No. C03-5878 JW (Related Cases: C03-5090 JW, C03-0415 JW and C02-5284 JW), filed Jan. 19, 2006, 76 pgs.
Aisaka et al., “NG-Monomethyl-L-arginine, an inhibitor of endothelium-derived nitric oxide synthesis, abbreviates acetylcholine-induced vasodilatation in the guinea-pig: Does nitric oxide regulate blood pressure in vivo?” Biochem. Biophys. Res. Commun., 1989, vol. 160, No. 2, pp. 881-886.
Das, U.N., “L-Arginine, Nitric Oxide and Collagen Vascular Diseases: A Potential Relationship?” Nutrition, 1992, vol. 8, No. 5, p. 371.
Fontaine et al., “Efficacy and tolerance of a new hematin in the treatment of an acute porphyria attack,” La Presse Medicale, 1987, vol. 16, No. 4, p. 177 (and English translation—2 pgs.).
Harrison's Principles of Internal Medicine, 10thEd., Petersdorf et al., eds., 1983, McGraw-Hill, Inc., pp. 25-27, 1465-1475.
Herrick et al., “Effect of haem arginate therapy on porphyrin metabolism and mixed function oxygenase activity in acute hepatic porphyria,” Lancet, 1987, vol. II:1178-1179.
Kohls et al., “Blood Serum Lipid Levels of Human Given Arginine, Lysine and Tryptophan Supplements Without Food,” Nutr. Rep. Intl., 1987, vol. 35, No. 1, pp. 5-13.
Kordac et al., “Haem arginate in acute hepatic porphyrias,” Br. Med. J., 1986, vol. 293, p. 1098.
Kordac et al., “Treatment of Acute Intermittent Porphyria,” Casopis Lekaru Ceskych, 1987, vol. 26, No. 944-948 (and English translation, 10 pgs.).
Kuvin et al., “A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression,” Am. Heart J., 2002, vol. 144, pp. 165-172.
Martas

Affiliated with

Also associated with

Rating

Enhancement of vascular function by modulation of endogenous... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhancement of vascular function by modulation of endogenous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of vascular function by modulation of endogenous... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4035600